Table Info

Table 1.

Biological functions of lysosomal hydrolases during liver fibrosis

Name (Family, MEROPS ID)	Biological process modulated during liver fibrosis
Name (Family, MEROPS ID)	Apoptosis	HSC activation	Autophagy	Inflammation	ECM remodeling
Cathepsin A (Ser, S10.002)	-	-	Degradation of LAMP2a restricting chaperone-mediated autophagy in vitro [48]	-	-
Cathepsin B (Cys, C01.060)	Proteolytic processing of members of the Bcl-2 family in hepatocytes [24]	Modulation of pAkt in HSC after PDGF stimulation contributing to their proliferative and migratory capacity [30]	Cytosolic cathepsin B, released by autophagic flux, triggers activation of NLRP3 in HSC contributing its activation [36]	Participation in the cytotoxic response mediated by TRAIL in NK/NKT cells by an unknown mechanism [39]	Collagenolytic activity by an unknown mechanism [43, 44]
Cathepsin B (Cys, C01.060)		Proteolysis of PDGF receptor-β contributing to PDGF-BB desensitization in HSC [31]		Modulation NF-κB dependent inflammation in HSC via sirtuin-1 regulation [40]	Collagenolytic activity by an unknown mechanism [43, 44]
Cathepsin D (Asp, A01.009)	Proteolytic cleavage of Bid into t-Bid, upstream mitochondria, triggered by TNF-α in hepatocytes [46]	Paracrine activation of cathepsin B in HSC contributing its activation [30]	Correlation of cathepsin D and autophagy during DR in cirrhosis by an unknown mechanism [47]	-	-
Cathepsin F (Cys, C01.018)	-	Transcriptional regulation of markers of HSC activation by an unknown mechanism [35]	-	-	-
Cathepsin H (Cys, C01.040)	-	Modulation of metalloproteinases gene expression in HSC via stabilization of class Iia histone deacetylases [34]	-	-	-
Cathepsin L (Cys, C01.032)	-	-	-	-	Collagenolytic activity by an unknown mechanism [44]
Cathepsin S (Cys, C01.034)	-	-	-	Modulation of NF-κB dependent inflammation in HSC via sirtuin-1 regulation [40]	-
Cathepsin S (Cys, C01.034)	-	-	-	Processing of CD74 contributing to antigen presentation in HSC [41]	-

pAkt: phosphorylated Akt; -: not applicable

Declarations

Acknowledgments

We would like to sincerely acknowledge all the authors, cited or not, whose work has contributed to the advancement of the research field.

Author contributions

MFF: Writing—original draft. PRB: Writing—original draft. JCP: Writing—original draft. AM: Writing—original draft, Conceptualization, Visualization, Supervision, Funding acquisition, Resources, Project administration, Writing—review & editing.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

AM’s research is supported by grants [RTI2018-097475-A-100] and [PID2021-123652OB-I00] funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union”. Both MFF and PRB salaries were supported by FPU fellowships ([FPU20/01367] and [FPU19/05357], respectively) awarded by the Ministry of Universities, Spain. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Bonam SR, Wang F, Muller S. Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019;18:923–48. [DOI] [PubMed] [PMC]

Turk V, Stoka V, Vasiljeva O, Renko M, Sun T, Turk B, et al. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim Biophys Acta. 2012;1824:68–88. [DOI] [PubMed] [PMC]

Talukdar R, Sareen A, Zhu H, Yuan Z, Dixit A, Cheema H, et al. Release of cathepsin B in cytosol causes cell death in acute pancreatitis. Gastroenterology. 2016;151:747–58.e5. [DOI] [PubMed] [PMC]

Vidak E, Javoršek U, Vizovišek M, Turk B. Cysteine cathepsins and their extracellular roles: shaping the microenvironment. Cells. 2019;8:264. [DOI] [PubMed] [PMC]

Tamhane T, Lllukkumbura R, Lu S, Maelandsmo GM, Haugen MH, Brix K. Nuclear cathepsin L activity is required for cell cycle progression of colorectal carcinoma cells. Biochimie. 2016;122:208–18. [DOI] [PubMed]

Mason SD, Joyce JA. Proteolytic networks in cancer. Trends Cell Biol. 2011;21:228–37. [DOI] [PubMed] [PMC]

Bose SJ, Ayagama T, Burton RAB. Chapter 3 - lysosomal proteases and their role in signaling pathways. In: Zelanis André, editor. Proteolytic signaling in health and disease. Academic Press; 2022. pp. 41–61. [DOI]

De Pasquale V, Moles A, Pavone LM. Cathepsins in the pathophysiology of mucopolysaccharidoses: new perspectives for therapy. Cells. 2020;9:979. [DOI] [PubMed] [PMC]

Drobny A, Prieto Huarcaya S, Dobert J, Kluge A, Bunk J, Schlothauer T, et al. The role of lysosomal cathepsins in neurodegeneration: mechanistic insights, diagnostic potential and therapeutic approaches. Biochim Biophys Acta Mol Cell Res. 2022;1869:119243. [DOI] [PubMed]

10.

Oikonomopoulou K, Diamandis EP, Hollenberg MD, Chandran V. Proteinases and their receptors in inflammatory arthritis: an overview. Nat Rev Rheumatol. 2018;14:170–80. [DOI] [PubMed]

11.

Ruiz-Blázquez P, Pistorio V, Fernández-Fernández M, Moles A. The multifaceted role of cathepsins in liver disease. J Hepatol. 2021;75:1192–202. [DOI] [PubMed]

12.

Cocchiaro P, De Pasquale V, Della Morte R, Tafuri S, Avallone L, Pizard A, et al. The multifaceted role of the lysosomal protease cathepsins in kidney disease. Front Cell Dev Biol. 2017;5:114. [DOI] [PubMed] [PMC]

13.

Surrey LF, Frank R, Zhang PJ, Furth EE. TTF-1 and napsin-A are expressed in a subset of cholangiocarcinomas arising from the gallbladder and hepatic ducts: continued caveats for utilization of immunohistochemistry panels. Am J Surg Pathol. 2014;38:224–7. [DOI] [PubMed]

14.

Lunde NN, Bosnjak T, Solberg R, Johansen HT. Mammalian legumain – a lysosomal cysteine protease with extracellular functions? Biochimie. 2019;166:77–83. [DOI] [PubMed]

15.

Markmann S, Thelen M, Cornils K, Schweizer M, Brocke-Ahmadinejad N, Willnow T, et al. Lrp1/LDL receptor play critical roles in mannose 6-phosphate-independent lysosomal enzyme targeting. Traffic. 2015;16:743–59. [DOI] [PubMed]

16.

Linebaugh BE, Sameni M, Day NA, Sloane BF, Keppler D. Exocytosis of active cathepsin B. Enzyme activity at pH 7.0, inhibition and molecular mass. Eur J Biochem. 1999;264:100–9. [DOI] [PubMed]

17.

Hartley BS. Proteolytic enzymes. Annu Rev Biochem. 1960;29:45–72. [DOI] [PubMed]

18.

Rawlings ND, Barrett AJ, Bateman A. MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res. 2012;40:D343–50. [DOI] [PubMed] [PMC]

19.

Nakken B, Varga T, Szatmari I, Szeles L, Gyongyosi A, Illarionov PA, et al. Peroxisome proliferator-activated receptor γ-regulated cathepsin D is required for lipid antigen presentation by dendritic cells. J Immunol. 2011;187:240–7. [DOI] [PubMed]

20.

Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer. 2006;6:764–75. [DOI] [PubMed]

21.

Mittal S, Mir RA, Chauhan SS. Post-transcriptional regulation of human cathepsin L expression. Biol Chem. 2011;392:405–13. [DOI] [PubMed]

22.

Katunuma N. Posttranslational processing and modification of cathepsins and cystatins. J Signal Transduct. 2010;2010:375345. [DOI] [PubMed] [PMC]

23.

Ochieng J, Chaudhuri G. Cystatin superfamily. J Health Care Poor Underserved. 2010;21:51–70. [DOI] [PubMed] [PMC]

24.

Werneburg NW, Guicciardi ME, Bronk SF, Kaufmann SH, Gores GJ. Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins. J Biol Chem. 2007;282:28960–70. [DOI] [PubMed]

25.

Werneburg N, Guicciardi ME, Yin XM, Gores GJ. TNF-α-mediated lysosomal permeabilization is FAN and caspase 8/Bid dependent. Am J Physiol Gastrointest Liver Physiol. 2004;287:G436–43. [DOI] [PubMed]

26.

Canbay A, Guicciardi ME, Higuchi H, Feldstein A, Bronk SF, Rydzewski R, et al. Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest. 2003;112:152–9. [DOI] [PubMed] [PMC]

27.

Guicciardi ME, Deussing J, Miyoshi H, Bronk SF, Svingen PA, Peters C, et al. Cathepsin B contributes to TNF-α-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest. 2000;106:1127–37. [DOI] [PubMed] [PMC]

28.

Guicciardi ME, Miyoshi H, Bronk SF, Gores GJ. Cathepsin B knockout mice are resistant to tumor necrosis factor-α-mediated hepatocyte apoptosis and liver injury: implications for therapeutic applications. Am J Pathol. 2001;159:2045–54. [DOI] [PubMed]

29.

Duran-Güell M, Flores-Costa R, Casulleras M, López-Vicario C, Titos E, Díaz A, et al. Albumin protects the liver from tumor necrosis factor α-induced immunopathology. FASEB J. 2021;35:e21365. [DOI] [PubMed]

30.

Moles A, Tarrats N, Fernández-Checa JC, Marí M. Cathepsins B and D drive hepatic stellate cell proliferation and promote their fibrogenic potential. Hepatology. 2009;49:1297–307. [DOI] [PubMed] [PMC]

31.

Okuyama H, Shimahara Y, Kawada N, Seki S, Kristensen DB, Yoshizato K, et al. Regulation of cell growth by redox-mediated extracellular proteolysis of platelet-derived growth factor receptor β. J Biol Chem. 2001;276:28274–80. [DOI] [PubMed]

32.

Moles A, Tarrats N, Morales A, Domínguez M, Bataller R, Caballería J, et al. Acidic sphingomyelinase controls hepatic stellate cell activation and in vivo liver fibrogenesis. Am J Pathol. 2010;177:1214–24. [DOI] [PubMed] [PMC]

33.

Moles A, Tarrats N, Fernández-Checa JC, Marí M. Cathepsin B overexpression due to acid sphingomyelinase ablation promotes liver fibrosis in Niemann-Pick disease. J Biol Chem. 2012;287:1178–88. [DOI] [PubMed] [PMC]

34.

Yang Z, Liu Y, Qin L, Wu P, Xia Z, Luo M, et al. Cathepsin H–mediated degradation of HDAC4 for matrix metalloproteinase expression in hepatic stellate cells: implications of epigenetic suppression of matrix metalloproteinases in fibrosis through stabilization of class IIa histone deacetylases. Am J Pathol. 2017;187:781–97. [DOI] [PubMed] [PMC]

35.

Maubach G, Lim MCC, Zhuo L. Nuclear cathepsin F regulates activation markers in rat hepatic stellate cells. Mol Biol Cell. 2008;19:4238–48. [DOI] [PubMed] [PMC]

36.

Tao Y, Qiu T, Yao X, Jiang L, Wang N, Jia X, et al. Autophagic-CTSB-inflammasome axis modulates hepatic stellate cells activation in arsenic-induced liver fibrosis. Chemosphere. 2020;242:124959. [DOI] [PubMed]

37.

Inzaugarat ME, Johnson CD, Holtmann TM, McGeough MD, Trautwein C, Papouchado BG, et al. NLR family pyrin domain-containing 3 inflammasome activation in hepatic stellate cells induces liver fibrosis in mice. Hepatology. 2019;69:845–59. [DOI] [PubMed] [PMC]

38.

Bestion E, Jilkova ZM, Mège JL, Novello M, Kurma K, Pour STA, et al. GNS561 acts as a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition. Ther Adv Chronic Dis. 2020;11:2040622320942042. [DOI] [PubMed] [PMC]

39.

Kahraman A, Barreyro FJ, Bronk SF, Werneburg NW, Mott JL, Akazawa Y, et al. TRAIL mediates liver injury by the innate immune system in the bile duct–ligated mouse. Hepatology. 2008;47:1317–30. [DOI] [PubMed] [PMC]

40.

de Mingo Á, de Gregorio E, Moles A, Tarrats N, Tutusaus A, Colell A, et al. Cysteine cathepsins control hepatic NF-κB-dependent inflammation via sirtuin-1 regulation. Cell Death Dis. 2016;7:e2464. [DOI] [PubMed] [PMC]

41.

Maubach G, Lim MCC, Kumar S, Zhuo L. Expression and upregulation of cathepsin S and other early molecules required for antigen presentation in activated hepatic stellate cells upon IFN-γ treatment. Biochim Biophys Acta. 2007;1773:219–31. [DOI] [PubMed]

42.

Kucharz E. Clinical and experimental studies on collagen metabolism in hepatic disorders. Med Interne. 1984;22:129–40. [PubMed]

43.

Murawaki Y, Hirayama C. Hepatic collagenolytic cathepsin in patients with chronic liver disease. Clin Chim Acta. 1980;108:121–8. [DOI] [PubMed]

44.

Leto G, Tumminello FM, Pizzolanti G, Montalto G, Soresi M, Gebbia N. Lysosomal cathepsins B and L and Stef in A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: potential clinical implications. Oncology. 1997;54:79–83. [DOI] [PubMed]

45.

Yamamoto H, Murawaki Y, Kawasaki H. Collagenolytic cathepsin B and L activity in experimental fibrotic liver and human liver. Res Commun Chem Pathol Pharmacol. 1992;76:95–112. [PubMed]

46.

Heinrich M, Neumeyer J, Jakob M, Hallas C, Tchikov V, Winoto-Morbach S, et al. Cathepsin D links TNF-induced acid sphingomyelinase to Bid-mediated caspase-9 and -3 activation. Cell Death Differ. 2004;11:550–63. [DOI] [PubMed]

47.

Hung TM, Yuan RH, Huang WP, Chen YH, Lin YC, Lin CW, et al. Increased autophagy markers are associated with ductular reaction during the development of cirrhosis. Am J Pathol. 2015;185:2454–67. [DOI] [PubMed]

48.

Cuervo AM, Mann L, Bonten EJ, d’Azzo A, Dice JF. Cathepsin A regulates chaperone-mediated autophagy through cleavage of the lysosomal receptor. EMBO J. 2003;22:47–59. [DOI] [PubMed] [PMC]

49.

Yang WL, Li Q, Sun J, Huat Tan S, Tang YH, Zhao MM, et al. Potential drug discovery for COVID-19 treatment targeting cathepsin L using a deep learning-based strategy. Comput Struct Biotechnol J. 2022;20:2442–54. [DOI] [PubMed] [PMC]

50.

Fuchs N, Meta M, Schuppan D, Nuhn L, Schirmeister T. Novel opportunities for cathepsin S inhibitors in cancer immunotherapy by nanocarrier-mediated delivery. Cells. 2020;9:2021. [DOI] [PubMed] [PMC]